These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 8385480

  • 1. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
    Saitoh S, Saito T, Otake A, Owada T, Mitsugi M, Hashimoto H, Maruyama Y.
    Arterioscler Thromb; 1993 Apr; 13(4):563-70. PubMed ID: 8385480
    [Abstract] [Full Text] [Related]

  • 2. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D.
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [Abstract] [Full Text] [Related]

  • 3. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 4. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP.
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [Abstract] [Full Text] [Related]

  • 5. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
    Shebuski RJ, Stabilito IJ, Sitko GR, Polokoff MH.
    Circulation; 1990 Jul; 82(1):169-77. PubMed ID: 2114233
    [Abstract] [Full Text] [Related]

  • 6. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, Fallon JT, Saito T, Collen D.
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [Abstract] [Full Text] [Related]

  • 7. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT.
    Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
    [Abstract] [Full Text] [Related]

  • 8. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
    Yasuda T, Gold HK, Leinbach RC, Saito T, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D.
    J Am Coll Cardiol; 1990 Dec; 16(7):1728-35. PubMed ID: 2123910
    [Abstract] [Full Text] [Related]

  • 9. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
    Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H.
    Circulation; 1995 Feb 15; 91(4):1175-81. PubMed ID: 7850956
    [Abstract] [Full Text] [Related]

  • 10. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec 15; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 11. Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model.
    Saito T, Saitoh S, Asakura T, Kanke M, Owada K, Maruyama Y.
    Int J Cardiol; 1993 Mar 15; 38(3):225-33. PubMed ID: 8463004
    [Abstract] [Full Text] [Related]

  • 12. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.
    Gold HK, Coller BS, Yasuda T, Saito T, Fallon JT, Guerrero JL, Leinbach RC, Ziskind AA, Collen D.
    Circulation; 1988 Mar 15; 77(3):670-7. PubMed ID: 3124974
    [Abstract] [Full Text] [Related]

  • 13. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
    Holahan MA, Mellott MJ, Garsky VM, Shebuski RJ.
    Pharmacology; 1991 Mar 15; 42(6):340-8. PubMed ID: 1946598
    [Abstract] [Full Text] [Related]

  • 14. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis.
    Sakamoto T, Ogawa H, Yasue H, Oda Y, Kitajima S, Tsumoto K, Mizokami H.
    Circulation; 1994 Jul 15; 90(1):427-32. PubMed ID: 8026029
    [Abstract] [Full Text] [Related]

  • 15. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
    Johns JA, Gold HK, Leinbach RC, Yasuda T, Gimple LW, Werner W, Finkelstein D, Newell J, Ziskind AA, Collen D.
    Circulation; 1988 Sep 15; 78(3):546-56. PubMed ID: 3136953
    [Abstract] [Full Text] [Related]

  • 16. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
    Yasuda T, Gold HK, Fallon JT, Leinbach RC, Garabedian HD, Guerrero JL, Collen D.
    J Am Coll Cardiol; 1989 May 15; 13(6):1409-14. PubMed ID: 2495318
    [Abstract] [Full Text] [Related]

  • 17. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.
    Nicolini FA, Nichols WW, Mehta JL, Saldeen TG, Schofield R, Ross M, Player DW, Pohl GB, Mattsson C.
    J Am Coll Cardiol; 1992 Jul 15; 20(1):228-35. PubMed ID: 1607530
    [Abstract] [Full Text] [Related]

  • 18. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons.
    Kohmura C, Gold HK, Yasuda T, Holt R, Nedelman MA, Guerrero JL, Weisman HF, Collen D.
    Arterioscler Thromb; 1993 Dec 15; 13(12):1837-42. PubMed ID: 8241105
    [Abstract] [Full Text] [Related]

  • 19. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr 15; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 20. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA, Anderson RD, MacCord CS, Scott H, Serebruany V, Herzog WR.
    Coron Artery Dis; 1994 Nov 15; 5(11):929-36. PubMed ID: 7719525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.